In the saga that never seems to end, it's reasonable that your usual brand of Coronavirus needs a refresh.

Enter Omicron, the all new, improved pathogen. It's the best one yet!

With an increasing sense of déjà vu, we talk about its increasing prevalence, and soon to be dominance, in our world. What impact is there on the big pharma companies? Should we invest in them now?

Wanting to get in on the action, we plan ahead to the variant after Omicron, one that will avoid all detection and show no symptoms.